PGP Farmer Secures €3M for EU-GMP Medical Cannabis Hub in France

PARIS – French biotech company PGP Farmer announced the completion of a €3 million funding round from private investors. The capital obtained will help advance the company’s plans to establish a large-scale, EU-GMP compliant production facility for medical Cannabis in France.

Led by co-founder and CEO Brahim Sebart, PGP Farmer aims to position France as a major supplier in Europe’s growing medical Cannabis market. The company highlights that European demand for medical Cannabis exceeds 20% annual growth, with roughly 75% of Cannabis flower currently imported, much of it from Canada. Germany, the continent’s largest market, imported nearly 200 tons in 2025 alone. France’s location offers logistical advantages for exports across the region.

The project centers on a 9-hectare site in France featuring advanced greenhouse cultivation and a pharmaceutical processing lab. A building permit has already been secured. Once operational, the facility is designed to deliver a fully controlled supply chain meeting GACP and EU-GMP standards. Long-term output could reach up to 30 tons annually.

“This funding supports our goal to build a model of excellence centered on export while reducing Europe’s reliance on imports,” Sebart said in a statement. He added that the initiative seeks to make France a central hub for high-quality medical Cannabis in Europe.

The timing aligns with France’s expected nationwide rollout of medical Cannabis access, following a pilot program that treated over 3,000 patients for conditions such as neuropathic pain, severe epilepsy, multiple sclerosis, and oncology or palliative care. PGP Farmer, a member of industry group UIVEC, contributed to a joint dossier submitted to France’s National Authority for Health (HAS) to inform regulatory decisions.

Europe’s medical Cannabis patient population is projected to surpass 1.5 million in 2026, creating sustained demand for domestic production that meets strict pharmaceutical requirements. PGP Farmer’s focus on traceability and innovation could help address supply chain vulnerabilities tied to heavy import dependence.

The company plans to participate in the Cannabis Europa Paris event on February 19, 2026, where Sebart will join a panel discussion on scaling French-made medical Cannabis.

As France maneuvers through the extended medical Cannabis pilot program set forth by at least mid-2026 and prepares for a permanent, pharmaceutical-style regime, PGP Farmer’s move exemplifies the initial positioning of domestic players. With patient numbers potentially climbing toward hundreds of thousands in the coming decade and heavy reliance on imports persisting in the short term, local facilities built and certified to EU-GMP standards could gradually shift the balance toward greater self-sufficiency and export capability.

Ultimately, whether PGP Farmer achieves its 30-ton target will depend on securing additional capital, navigating final reimbursement rules, and proving consistent quality against global competitors. For now, the investment highlights a calculated bet on France’s pharmaceutical heritage and agricultural capacity to capture a meaningful share of Europe’s growing demand for therapeutic Сannabis.

Images courtesy of pgpfarmer.fr